Keeping Track: Genmab/AbbVie Epkinly, Krystal’s Vyjuvek Join US FDA’s 2023 Novel Approvals List
Executive Summary
Oncology's surprisingly low numbers this year are among the latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
Santhera’s Vamorolone For DMD Among Orphan Drugs Up For EU Marketing Decision
The European Medicines Agency is this week due to decide whether to recommend pan-EU marketing authorization for a number of new products.
Keeping Track: Regeneron’s Bispecific Bid, More Regenerative Medicine BLAs, And Vadadustat Returns
Highlights of recent submissions for approval from the Pink Sheet’s US FDA Performance Tracker
Cool Down: US FDA’s July User Fee Calendar Suggests Slower Pace After Torrid June
FDA action is expected on a handful of novel agents, including Daiichi Sankyo’s quizartinib, and conversion to full approval for Eisai/Biogen’s Leqembi.